JosephBaarMD

Oncology • Cleveland, OH

Associate Professor, Medicine, Case Western Reserve University School of Medicine

Join to view full profile

Dr. Baar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Baar's full profile

Already have an account?

Office
11100 Euclid Ave
Cleveland, OH 44106
Phone+1 216-844-8500

Education & Training

Newton-Wellesley HospitalResidency, Internal Medicine, 1986 - 1987
University of Western OntarioClass of 1984

Certifications & Licensure

OH State Medical License 2006 - 2023
PA State Medical License 1994 - 2014
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

Fellow (FACP) American College of Physicians, 2003

Clinical Trials

S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo Start of enrollment: 2006 Oct 01
Completed
Phase 3
Epothilone B in Treating Patients With CNS Metastases From Breast Cancer Start of enrollment: 2007 Jan 01
Completed
Phase 2
Fatigue Caused by Chemotherapy in Women Who Have Undergone Surgery for Breast Cancer and in Healthy Volunteers Start of enrollment: 2008 Jul 01
Terminated
Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases Start of enrollment: 2009 Dec 01
Completed
Early Phase 1
MUC1 Vaccine for Triple-negative Breast Cancer Start of enrollment: 2009 Aug 19
Completed
Early Phase 1
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
Type I-Polarized Autologous Dendritic Cell Vaccine With Tumor Blood Vessel Antigen-Derived Peptides in Metastatic Breast Cancer Patients Start of enrollment: 2015 Jul 17
Completed
Phase 1
Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer Start of enrollment: 2017 May 19
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

2 citations
Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer.
Avia D Wilkerson, Prerana Bangalore Parthasarathy, Nickolas Stabellini, Carley Mitchell, Paul G Pavicic Jr
Clinical Cancer Research. 2024-01-05
23 citations
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitor...
Kerin B. Adelson, Bhuvaneswari Ramaswamy, Joseph A. Sparano, Paul J. Christos, John J. Wright
NPJ Breast Cancer. 2016-12-14
20 citations
Phase II trial of patupilone in patients with brain metastases from breast cancer
David M. Peereboom, Conleth G. Murphy, Manmeet Ahluwalia, Alison Conlin, April F. Eichler
Neuro-Oncology. 2014-04-01

Press Mentions

UH Seidman Cancer Center Expert Presents Triple-Negative Breast Cancer Immunotherapy TrialDecember 8th, 2016

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American College of Physicians - ACP
Fellow